Expert Interview
Understanding how Halozyme’s Enhanze fits in the drug delivery market space, and its prospect for the future
Ticker(s): HALO, ROG.VXA physician who has experience treating patients in the target indications for Enhanze development. Ideally one of the larger indications.
Please tell us about yourself, your experience, type of practice you have (academic or private).
Added By: joe_mccannWhat's your view on Enhanze and the need for Sub-q formulations for the IV drugs you prescribe to patients?
Added By: joe_mccannIs there value in Enhaze working with chemotherapy treatments? How many of the patients would be willing to pay extra for the subcutaneous infusion, rather than just doing the regular schedule that can take hours?
How much more subcutaneous bulk fluid flow does Enhanze facilitate, versus other similar subQ delivery methods? How efficient is it at degrading hyaluronan, in comparison with other spreading agents that you may know of?
Added By: joe_mccannWhat’s your knowledge about Herceptin SC in early breast cancer? Does the 5 mins duration vs 30-90 make a compelling argument for its use, in your opinion? How much would you save in medical staff expenses, vs the longer duration infusion?
Added By: joe_mccannAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
